secwatch.observer — SEC 8-K summary
======================================

Issuer:     Atara Biotherapeutics, Inc. (ATRA)
CIK:        0001604464
Form:       8-K
Filed at:   2024-09-03T23:59:59+00:00
Accession:  0001193125-24-212168
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Atara raises ~$36M via registered direct offering; appoints Gregory Ciongoli to board
--------------------------------------------------------------------------------

- Registered direct offering of 758,900 shares and pre-funded warrants for up to 3,604,780 shares at $8.25/$8.2499.
- Gross proceeds ~$36M; net proceeds for working capital and general corporate purposes.
- Adiumentum Capital Fund I LP (Ciongoli is Managing Partner) purchases $7.5M of the offering.
- Gregory A. Ciongoli appointed to Board of Directors effective upon closing on September 5, 2024.
- Ciongoli is independent, not receiving director compensation; standard indemnification agreement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1604464/000119312524212168/0001193125-24-212168-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1604464/000119312524212168/d852765d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-212168

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer